- New Migraine Friendly Workplace Stamp developed by the European
Migraine & Headache Alliance recognises organizations who
support their employees who suffer from migraine - a severe and
debilitating health condition
- Teva helped pioneer the European initiative with the European
Migraine and Headache Alliance
AMSTERDAM, July 13,
2022 /PRNewswire/ -- Teva Pharmaceuticals Europe B.V.
has today been accredited the Migraine Friendly Workplace Stamp.
This new initiative recognizes companies that are committed to
providing a "friendly" migraine work environment for their
employees, whether they suffer from migraine or work with
colleagues who are afflicted by this condition.
Teva helped pioneer and financially supported the development of
this initiative in 2021 with the European Migraine & Headache
Alliance (EMHA), working with an expert panel of migraine experts
around Europe, including
neurologists and physicians in occupational medicine, to develop
the program.
The initiative was established in recognition that 41 million
people in Europe live with
migraine[1] resulting in significant personal impact and
burden in the workplace. The severity of migraine has been shown in
many studies including Teva's own European survey of 12,545 adults
with migraine - 'Beyond Migraine' - in which 49% of sufferers said
their migraine diminished their ability to function effectively in
the workplace.[2] The Migraine Friendly Workplace Stamp
aims to provide employers with tools to support their employees who
suffer from migraine, and highlights their commitment to creating a
migraine friendly work environment.
The Migraine Friendly Stamp program is designed to reduce the
impact of migraine in the workplace and recognizes companies that
undertake EMHA training as well as creating the right environment
in the workplace (this ranges from availability of water fountains
to dark rooms.)
Proud to support and be part of this initiative, Teva's goal is to
help many migraine sufferers feel more comfortable and less
stigmatized in the workplace, and not have to hide a part of who
they are, whether that's suffering from migraine or even greater
aspects of diversity.
Richard Daniell, EVP Head of
Europe Commercial at Teva Pharmaceuticals commented: "The Migraine
Friendly Stamp is a fantastic step forwards in helping our
employees who suffer with migraine to get the support that they
need within the workplace. Migraine is an important area of focus
for Teva, many patients remain under diagnosed and struggle to
receive correct treatment. This initiative mirrors our overall
commitment to improving the well-being of migraine patients in all
spheres of their lives."
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE
and TASE: TEVA) has been developing and producing medicines to
improve people's lives for more than a century. We are a global
leader in generic, biosimilar and specialty medicines with a
portfolio consisting of over 3,500 products in nearly every
therapeutic area. Around 200 million people around the world take a
Teva medicine every day and are served by one of the largest and
most complex supply chains in the pharmaceutical industry. Along
with our established presence in generics, we have significant
innovative research and operations supporting our growing portfolio
of specialty and biopharmaceutical products. Learn more at
www.tevapharm.com
About The European Migraine & Headache
Alliance
The European Migraine & Headache Alliance is a
non-profit umbrella organization that includes over 33 patient
associations for Migraine, Cluster Headache, Trigeminal Neuralgia
and other headache diseases, across Europe. The Alliance was launched in 2006 and
since then, being the development of European umbrella
organizations a natural progression with more relevance for
European nations. Our aim is to speak on behalf of and to advocate
for the rights and needs of the 138 million people in Europe living with headache disorders. EMHA is
an active member of the European Federation of Neurological
Alliances [EFNA], the International Association of Patient
Organizations [IAPO], the European Patients Forum [EPF] and also
works closely with organizations such as the European Headache
Federation [EHF], European Brain Council [EBC] and others.
www.emhalliance.org/
[1] Stovner, L. J., Andrée, C., & Eurolight
Steering Committee (2008). Impact of headache in Europe: a review for the Eurolight project.
The journal of headache and pain, 9(3), 139–146.
https://doi.org/10.1007/s10194-008-0038-6
[2] Beyond Migraine – The Real You. Survey
conducted 2020. Teva Pharmaceuticals. Data on file.